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Abstract: Eisenmenger syndrome is the most severe form of pulmonary arterial hypertension and arises on the basis of 
congenital heart disease with a systemic-to-pulmonary shunt. Due to the chronic slow progressive hypoxemia with central 
cyanosis, adult patients with the Eisenmenger syndrome suffer from a complex and multisystemic disorder including co-
agulation disorders (bleeding complications and paradoxical embolisms), renal dysfunction, hypertrophic osteoarthropa-
thy, heart failure, reduced quality of life and premature death. 
For a long time, therapy has been limited to symptomatic options or lung or combined heart-lung transplantation. As new 
selective pulmonary vasodilators have become available and proven to be beneficial in various forms of pulmonary arte-
rial hypertension, this targeted medical treatment has been expected to show promising effects with a delay of deteriora-
tion also in Eisenmenger patients. Unfortunately, data in Eisenmenger patients suffer from small patient numbers and a 
lack of randomized controlled studies. 
To optimize the quality of life and the outcome, referral of Eisenmenger patients to spezialized centers is required. In such 
centers, specific interdisciplinary management strategies of physicians specialized on congenital heart diseases and PAH 
should be warranted.  
This medical update emphasizes the current diagnostic and therapeutic options for Eisenmenger patients with particularly 
focussing on epidemiology, clinical aspects and specific diagnostic options. 
Keywords: Cardiovascular diseases, adult congenital heart defects, pulmonary hypertension, Eisenmenger syndrome, follow-
up studies, Competence Network for Congenital Heart Defects. 
1. INTRODUCTION 
  The revised classification system defined during the 3
rd 
World symposium on PAH held in 2003 in Venice, Italy, 
included several improvements over the former 1998 Evian 
Classification system [1].  
  Slight modifications were proposed during the 4
th World 
symposium on PAH held 2008 in Dana Point, USA (Table 
2), also being reflected in the ESC-Guidelines for diagnosis 
and treatment of pulmonary hypertension [2], which have 
significant impact on the management strategies of PAH in 
congenital heart disease (Table 1). 
Overall, the classification system of pulmonary hypertension 
can be summarized as: 
o  WHO Group I - Pulmonary arterial hypertension (PAH) 
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o  WHO Group II - Pulmonary hypertension associated 
with left heart disease 
o  WHO Group III - Pulmonary hypertension associated 
with lung diseases and/ or hypoxemia 
o  WHO Group IV - Pulmonary hypertension due to 
chronic thrombotic and/ or embolic disease 
o  WHO Group V - Miscellaneous. 
  Congenital cardiac anomalies, associated with PAH, are 
represented in Group 1 in this clinical classification system. 
  Until recently pulmonary arterial hypertension (PAH) 
was defined by a mean pulmonary artery pressure (PAP) of 
more than 25 mmHg at rest or more than 30 mmHg during 
exercise. A short time ago, a new grading has been proposed 
during the 4
th World symposium on PAH 2008 in Dana 
Point, USA [3]. Now, the preassigned upper limit of the 
normal mean PAP at rest will be 20 mmHg, while 21-24 
mmHg is termed “borderline-PAH”, and a mean PAP of 
more than 25 mmHg as “manifest” PAH [4]. Pulmonary ar-
tery wedge pressure, cardiac output and the derived parame-344    Current Cardiology Reviews, 2010, Vol. 6, No. 4  Kaemmerer et al. 
ters will not be taken into account, and PAH during exercise 
will not any longer be used for defining PAH.  
  The most severe form of PAH related to congenital car-
diac anomalies (CCD) is called Eisenmenger Syndrome 
(ES). 
  The first clinical description originates from the Viennese 
physician Victor Eisenmenger (29.  Jan.  1864 - 11.  Dec. 
1932). In 1897 he reported on a 32-year-old man with cyano-
sis and dyspnea since infancy [5, 6]. This patient had a rea-
sonably active life until 3 years before his death, when dys-
pnea increased and right heart failure began. He succumbed 
suddenly after massive hemoptysis. Autopsy revealed a non-
restrictive membranous malalignment ventricular septal de-
fect (VSD), marked right ventricular hypertrophy, an over-
riding aorta, and atheromatosis of the major pulmonary arter-
ies. In this paper neither pulmonary artery pressure nor pul-
monary vascular disease were discussed [6]. 
  During 60 years following Eisenmenger´s report only 
little insight was gained into the pathophysiology of this dis-
ease. In 1951 Paul Wood referred for the first time to the 
pathophysiology of Eisenmenger syndrome (ES) or pulmo-
nary hypertension with reversed shunt, and in 1958 refined 
ES as “pulmonary hypertension due to a high pulmonary 
vascular resistance (PVR) with reversed or bidirectional 
shunt at aorto-pulmonary, ventricular or atrial level”. 
  Pulmonary arterial hypertension and pulmonary vascular 
disease are induced by uncorrected congenital cardiac 
anomalies with a primary left-to-right shunt. Over time, vas-
cular changes, and a decrease of the overall cross-sectional 
area develop in the pulmonary arteriolar bed. When two 
thirds of the pulmonary vascular bed is compromised, pul-
monary resistance and pressure increase. 
  Secondary to the elevated pulmonary artery pressures, the 
left-to-right shunt converts into a right-to-left shunt, resulting 
in desaturation of systemic arterial blood and cyanosis.  
 Today,  ES indicates any large congenital cardiac defect, 
no matter where it is located, permitting increased pulmo-
nary blood flow and transmission of elevated pressure to 
pulmonary circulation, causing a balanced or predominant 
right-to-left shunt secondary to a fixed and markedly ele-
vated pulmonary vascular resistance. Hemodynamically, 
Eisenmenger syndrome (ES) is defined as an elevation of the 
pulmonary vascular resistance to 12 Wood Units or to a 
pulmonary-to-systemic resistance ratio equal to or greater 
than 1.0 [7]. 
Table 1.  Management Algorithm for Pulmonary Arterial Hypertension in Congenital Heart Disease Patients (mod. ESC-Guidelines 
[2]) 
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Table 2.  Updated Clinical Classification of Pulmonary Hyper-
tension (Dana Point, 2008) [3] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted from Journal of the American College of Cardiology, Volume 54 No. 1, 
Suppl S, 2009, Simonneau et al, Updated Clinical Classification of Pulmonary Hyper-
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  For a very long time severe pulmonary hypertension in 
ES was believed irreversible and treatment was only symp-
tomatic. Recent advances in the medical treatment, however, 
may potentially reduce pulmonary artery resistance, reverse 
the process and improve clinical condition and survival in 
selected patients with systemic pressures in the pulmonary 
artery. Recent data on vasodilator treatment for PAH show 
that nearly one third of Eisenmenger patients maintain some 
degree of pulmonary vasoreactivity to inhaled NO [8], and 
even some reverse remodeling due to antiproliferative effects 
of endothelin receptor antagonists may occur [9]. 
  However, long-term results of this approach are lacking. 
It has to be kept in mind that pharmacological treatment of 
PAH in patients with persisting shunt lesions may even be 
precarious. This is completely different from people with 
idiopathic forms of PAH (iPAH). If the underlying defect 
remains uncorrected, the pharmocologically induced reduc-
tion of pulmonary vascular resistance may induce increased 
pulmonary flow, and even an increased pressure and shear 
stress, which, in turn, may intensify anatomic vascular chan-
ges. This may put the patients with persisting shunts into a 
high risk group and, perhaps, the long-term prognosis may 
worsen and become comparable with that of iPAH patients.  
  Moreover, the prognosis of the rare, primarily inoperable 
patients with a congenital cardiac defect (CCD) and a shunt 
who can be repaired after a positive response to pharma-
cotherapy is also uncertain. It is still unknown, if his ‘natu-
ral’ or unnatural history can be affected favorably, or, if his 
prognosis becomes worse and also converges to that of a 
patient with idiopathic forms of PAH. 
2. EPIDEMIOLOGY, NATURAL HISTORY AND 
CLINICAL COURSE 
 The  development of ES depends on the size of the shunt 
lesion and concomitant factors, such as the presence of 
Down syndrome. 
  Eisenmenger physiology is commonly established during 
the first one or two years of life if the shunt is aorto-
pulmonary or interventricular. The risk to develop ES de-
pends on the size and location of the shunt lesion. It may 
occur in congenital anomalies with a left-to-right shunt big 
enough to allow equalization of pressure between both ven-
tricles and/ or pulmonary artery, and not in patients with 
small shunts or septal defects associated with significant 
pulmonary stenosis. Particularly susceptible are patients with 
VSD, complete AV-septal defect, patent ductus arteriosus 
(PDA), aorto-pulmonary window, D-transposition of the 
great arteries and a VSD as well as a truncus arteriosus. Ma-
jor previously used systemic-to-pulmonary artery shunts 
such as Waterston- or Pott-shunts may also be associated 
with the development of ES. Large defects at the atrial level 
may also cause pulmonary hypertension, but usually less 
often, and not until the second or third decade of life. 
 The  prevalence of ES is not known. According to his-
torical data, about 8% of patients with congenital cardiac 
disease and 11% of those with left-to-right shunts develop 
the ES [10, 11]. Recent data are derived from the CONCOR 
(CONgenital COR vitia) registry, a nationwide registry of 
adult patients with congenital heart defects in the Nether-
lands [11]. The prevalence of PAH among 5970 registered 
adults with congenital heart disease (CHD) was 4.2%, one 
percent of all registered patients had the ES. Of 1824 patients 
with a septal defect and therefore prone to PAH, in the regis-
try 112 patients (6.1%) had PAH. Of these patients, 58% had 
the ES. Among the patients with a previously closed septal 
defect, 30 had PAH (3%).  
  The natural history of ES is comprised of a long symp-
tom-free time period. Patients have adjusted to a lower exer-
cise capacity since childhood. Patients may even do well 
throughout adolescence and early adulthood. Many become 
symptomatic during their 30s and gradually develop com-
plaints and complications, particularly cyanosis, exercise 
intolerance, dyspnea upon exertion, syncope, chest pain, 
stroke or brain abscesses, right sided congestive heart failure, 346    Current Cardiology Reviews, 2010, Vol. 6, No. 4  Kaemmerer et al. 
hyperviscosity complications, pulmonary hemorrhage/ he-
moptysis and endocarditis. Rhythm disturbances, particularly 
atrial fibrillation, corresponds to clinical deterioration and 
right heart failure. According to historical data, patients with 
ES usually die between 30 and 35 years [7]. However, sur-
vival to late adulthood has been reported. 
  Importantly, prognosis of patients with spontaneous ES is 
by far better than the prognosis of patients with idiopathic 
forms of PAH, although there are many similarities regard-
ing the histological changes [12], Fig. (1). The ventricular 
remodeling in patients with ES differs from that in patients 
with idiopathic pulmonary hypertension [13, 14]. The better 
prognosis of Eisenmenger patients is believed to be to the 
fact that the subpulmonary ventricle has been exposed to 
high pressures and has been primed since birth; it is better 
adapted because of the long-standing volume and pressure 
overload. Furthermore, regression of the physiologic right 
ventricular hypertrophy does not occur and the right-to-left 
shunt serves as an excess flow valve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Kaplan-Meier survival of patients with Eisenmenger syn-
drome and PPH [12]. 
Reprinted from Journal of Heart & Lung Transplant, Volume 15, 
1996, Hopkins et al, “Comparison of the hemodynamics and sur-
vival of adults with severe primary pulmonary hypertension or Eis-
enmenger syndrome”, Pages 100-105, Copyright (2008), with per-
mission from Elsevier. 
 
  The actuarial survival rate is 80% at 10 years, 77% at 15 
years 42% at 25 years [15, 16]. Most Eisenmenger patients 
die from sudden cardiac death, congestive heart failure, he-
moptysis, cerebral abscesses, thromboembolic events, from 
complications during pregnancy or due to noncardiac surgery 
[17].  
3. ANATOMY AND PATHOPHYSIOLOGY 
3.1. Anatomy 
  The Eisenmenger physiology is part of the spectrum of 
unoperated CHD, as mentioned above, but may also develop 
despite surgical repair of the underlying cardiac anomaly. 
Pulmonary vascular resistance plays the key role. Paul 
Wood’s strict definition of ES as severe systemic cyanosis 
due to reversal of the shunting at atrial, ventricular or great 
artery level theoretically excludes common atrium and 
anomalous pulmonary venous drainages, single ventricle, 
and truncus arteriosus. In these cases, cyanosis does not re-
sult from shunt reversal, but is the consequence of obligate 
intracardiac mixing of desaturated and oxygenised blood. 
This aspect is important for proper management of these 
diagnoses.  
  While the process to ES is usually interrupted with early 
surgical repair of the shunting lesion, pulmonary vascular 
disease may progress in late repair and individual cases. As a 
consequence, a hemodynamic situation similar to iPAH may 
result. 
3.2. Pathophysiology 
  The presence of an increased pulmonary blood flow and 
transmission of systemic pressure to the pulmonary arteries -
due to a nonrestrictive communication at any level between 
the systemic and pulmonary circulation- are the driving 
forces for the development of reactive pulmonary hyperten-
sion, which is followed by irreversible pulmonary vascular 
disease. 
  As a matter of principal, in patients with a primary left-
to-right shunt, the physiologic decrease of pulmonary vascu-
lar resistance early after birth results in an increased left-to-
right shunt (right-to-left shunting in transposition or mixed 
flow in single ventricle). It is likely that in patients with a 
large communication high flow causes mechanical stretch 
and intimal tears. Moreover, it produces progressive struc-
tural abnormalities and histological changes in the pulmo-
nary vasculature, which are accompanied by an increased 
production of intrinsic elastase and vascular endothelial 
growth factors. Endothelial and medial hypertrophy and 
pulmonary occlusive lesions can progress further [18, 19]. 
Furthermore, endothelin concentrations and serum throm-
boxane levels increase and induce endothelial dysfunction 
and platelet activation [20, 21]. Complex pathobiological 
processes cause pulmonary obstructive lesions and pulmo-
nary hypertension can develop, which result in decreased 
pulmonary blood flow in turn [22].  
  As long as PVR is lower than the systemic vascular resis-
tance, a predominant left-to-right shunt is present. Particu-
larly in children this situation is associated clinically with 
congestive heart failure.  
  As structural changes in the pulmonary artery progress 
and pulmonary vascular resistance rises, symptoms of con-
gestive heart failure disappear, and right-to-left shunt devel-
ops at the atrial, ventricular or the level of the great arteries. 
Cyanosis may initially be observed only on effort, but over 
time, cyanosis manifests at rest (ES).  
  The effect of the shunt depends on the exact location 
and its size (Table 3, 4). Shunts may cause different loading 
conditions and exert strain on the pulmonary vascular tree 
and the subpulmonary ventricle, and thus modify morbidity 
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Table 3.  Anatomic-Pathophysiologic Classification of Congeni-
tal Systemic-to-Pulmonary Shunts Associated With 
Pulmonary Arterial Hypertension (Modified From 
Venice 2003) [3] 
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Suppl S, 2009, Simonneau et al, Updated Clinical Classification of Pulmonary Hyper-
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I. Shunt at Atrial Level 
  Partial and total anomalous pulmonary venous drainage, 
sinus venosus defects, atrial septal defects, and common 
atrium:  
 
  These defects deliver mainly large blood volumes with-
out an increase of pressure and without shear stress to the 
pulmonary endothelium.  
 In  abnormally draining pulmonary veins, the shunt is 
fixed due to the abnormal connection. 
 In  atrial septal defects, the shunt volume can be large 
and may cause right heart dilatation. The amount of left-to-
right shunt correlates with right ventricular diastolic compli-
ance and will decrease with increasing right ventricular stiff-
ness. If PVR increases in the 3
rd and 4
th decade, an additional 
pressure load develops, and right ventricular myocardium 
may fail. Hence, cyanosis may worsen by the increased 
right-to-left shunt due to increased right ventricular filling 
pressure overload. 
II. Shunt at Ventricular Level 
  Atrio-ventricular and ventricular septal defects, and sin-
gle ventricle:  
  These defects deliver volume and, depending on size, 
pressure. In systole, the volume is directly ejected into the 
great arteries and depends on the Rp:Rs ratio and the ejecting 
power of the ventricles and ends with closure of the semilu-
nar valves. There may be a different shunt direction and vol-
ume in early and late diastole, which depends on ventricular 
compliance. This explains the angiographic and hemody-
namic findings of left-to-right shunting during systole and 
right-to-left shunting in diastole in the presence of a hyper-
trophied and stiff right ventricle.  
  The atrio-ventricular septal defect adds the atrial shunt 
physiology to this, i.e. contributes the volume load causing 
ventricular dilatation. In case of a large defect, the high pres-
sure postnatally maintains a high, near systemic PVR, avoid-
ing severe cyanosis and also avoiding transient heart failure. 
Cyanosis may not be marked and is discovered only when 
PVR becomes suprasystemic.  
III. Shunt at Arterial Level 
  Aortopulmonary window, persistent ductus arteriosus, 
and truncus arteriosus:  
  All shunts at arterial level deliver blood flow and sys-
temic pressure to the pulmonary vascular tree continuously 
during both systole and diastole and are therefore associated 
with an early and rapidly progressive rise of pulmonary vas-
cular resistance. 
Size of Shunt 
  Restriction versus large defects: 
  Below a certain size, the exact diameter of the defect 
does matter. The threshold is 2-3 cm at atrial level (limiting 
Qp:Qs ratio to 4-6-fold), and 1-1.5 cm at ventricular level 
(limiting Qp:Qs ratio to 3-4 fold), and 0.5-0.7 cm at arterial 
level [23].  
  On the contrary, if the entire septum is almost absent 
(e.g. in common atrium, single ventricle, truncus arteriosus), 
then complete mixing of the venous and arterialised blood 
occurs, and the resulting saturation is a function of the Qp:Qs 
ratio and is equal in both great arteries, with univentricular 
heart function.  
  Eisenmenger physiology may occur not only in unoper-
ated patients, but also postoperatively if communications 
between the systemic and pulmonary circulation persist. 
Surgically created systemic arterial to pulmonary shunts 
(Waterston- and Pott-shunts, and rarely Blalock-Taussig 
anastomosis) improve oxygen saturation, but at the expense 
of volume loading of the systemic ventricle. Blood flow 
through these non-restrictive shunts is frequently difficult to 
control and may result in pulmonary vasculopathy during 
follow-up, especially in adult patients.  348    Current Cardiology Reviews, 2010, Vol. 6, No. 4  Kaemmerer et al. 
3.3 Differences to Idiopathic Pulmonary Arterial Hyper-
tension 
Stimulus Known 
  In contrast to idiopathic PAH, the cause for the develop-
ment of increased PVR in patients with CHD is known and 
monitored. In some patient groups, however, the increase in 
PVR seems to be out-of-proportion to the stimulus, such as 
in children with persistent small ducts or insignificant atrial 
septal defects or transposition that is operated on in a timely 
fashion. 
Age Distribution 
  Idiopathic PAH can present at any age and seems to oc-
cur as early as in the first months of life and as late as in the 
seventh decade. Pediatric iPAH shows a progressive course, 
which only recently has been modified by available new 
drug treatments. In contrast, the development of increased 
PVR in CHD appears somewhat more predictable, being 
avoidable by surgical repair before 6 months of age and 
showing decades-long stability in ES.  
Right Ventricular Remodeling/Function 
  The right ventricle can chronically adapt to a large extent 
to increased afterload and maintain cardiac output until con-
tractility decreases. The subpulmonic ventricle in CHD may 
be congenitally malformed with different positions of atriov-
entricular and semilunar valves, hypoplasia or hypertrophy 
of the inflow, trabecular and infundibular portion or the sub-
pulmonic ventricle, and it may be surgically altered due to 
myocardial incisions and intraventricular and septal repair, 
conditions which affect contraction.  
4. CLINICAL PRESENTATION AND PHYSICAL   
EXAMINATION 
  Patients with ES often have a history of pulmonary con-
gestion during infancy due to the left-to-right shunt with 
increased pulmonary blood flow. With increasing pulmonary 
vascular resistance, the pulmonary flow declines and pulmo-
nary congestion decreases. The shunt will reverse and the 
patients become cyanotic with further increase in pulmonary 
vascular resistance. 
  Typical clinical signs and symptoms of adults with ES 
are dyspnea on exertion, fatigue, syncope due to low sys-
temic cardiac output, neurologic abnormalities (e.g. head-
ache, dizziness, visual disturbances) due to secondary eryth-
rocytosis and hyperviscosity, congestive right heart failure, 
arrhythmias, hemoptysis due to pulmonary infarction, rup-
ture of a dilated pulmonary artery or a thin-walled pulmo-
nary arteriole, bleeding due to coagulation abnormalities or 
thrombocytopenia, and cerebrovascular accidents due to hy-
perviscosity, paradoxical embolism, or a cerebral abscess. 
4.1. Physical Examination 
  Physical examination reveals central cyanosis and club-
bing. In case of a PDA differential cyanosis may occur, if 
desaturated blood enters the aorta distal to the left subclavian 
artery. The arterial pulse is often normal or diminished. The 
jugular venous pulse is normal without right heart failure, or 
reveals mild to moderate systemic venous pressure elevation 
with a prominent “a”-wave. In tricuspid regurgitation, the 
jugular venous pressure may be elevated and shows a promi-
nent "v" wave, Fig. (2).  
  A parasternal lift from the right ventricle is palpable in 
almost all patients. The left ventricular apical impulse is usu-
ally absent due to a posterior displacement. At the upper left 
sternal border a prominent main pulmonary artery impulse is 
present and a tactual closure of the pulmonary valve. 
  On auscultation many adults have a pulmonary ejection 
sound early in systole, and a loud 4
th heart sound. The pul-
monary component of the second heart sound is usually loud 
and single in the presence of non-restrictive ventricular sep-
tal defect. The widely and fixed split S2 persists in patients 
with an ASD. There is usually a spindle-shaped systolic 
murmur in the pulmonary area. An isodynamic holosystolic 
murmur of tricuspid regurgitation, which increases its inten-
sity in inspiration may occur at the left lower parasternal 
border. In case of pulmonic regurgitation a decrescendo 
murmur (Graham Steell murmur) is audible early in diastole 
over the left upper parasternal border. Murmurs of a ven-
tricular septal defect or a patent ductus arteriosus are lacking 
in patients with severe pulmonary hypertension. A third heart 
sound as well as hepatosplenomegaly or a pulsatile liver oc-
cur with right heart failure. 
Table 4.  Clinical Classification of Congenital Systemic-to-Pulmonary Shunts Associated to PAH [3]. 
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Fig. (2). Elevated jugular venous pressure and prominent "v" wave 
in right heart failure and severe tricuspid regurgitation.  
4.2. ECG 
 ECG shows right atrial enlargement (P-dextroatriale), 
right axis deviation, and right ventricular hypertrophy, in-
cluding tall R wave in V1/2, deep S waves in V5/6 ± ST- and 
T-wave abnormalities. Sometimes, these alterations are su-
perimposed by ECG signs of the underlying cardiac defect 
(e.g. left or biventricular hypertrophy in univentricular 
hearts, transposition of the great arteries (TGA), truncus arte-
riosus). Left axis deviation is typically seen in complete or 
incomplete AV-septal defects. Atrial or ventricular   
arrhythmias are often present, particularly in the presence of 
heart failure. A first-degree AV-block is common in AV-
septal defects. 
4.3. Lab-Studies 
  Pulse oximetry depicts decreased oxygen saturations in 
the cyanotic patient. Secondary erythrocytosis and hema-
tocrit levels greater than 65% are present in most Eisenmen-
ger patients as an adaptation to the low level of circulating 
oxyhemoglobin. Mean corpuscular hemoglobin and mean 
corpuscular volume may be low in iron deficient states (mi-
crocytosis, hypochromasia). However, despite of iron defi-
ciency hypochromasia and microcytosis are not as frequent 
as expected, whereas hyperchromasia and macrocytosis are 
relatively common [24]. Furthermore, many patients present 
with hyperhomocysteinemia, possibly related to folate or B-
vitamin deﬁciencies [24]. 
  For full evaluation of iron metabolism, serum ferritin and 
serum transferrin must be assessed in addition to the erythro-
cyte indexes and perhaps the soluble transferrin receptor, 
which is proportional to cellular iron requirements [24]. Uric 
acid and bilirubin levels are usually increased. 
4.4. Chest-X-Ray 
 Chest-x-ray varies with the underlying lesion, the mag-
nitude of the shunt and the duration of pulmonary vascular 
changes. Usually it reveals prominent, dilated main and 
branch pulmonary arteries. The peripheral pulmonary vessels 
are diminished in size and number (pruning), Fig. (3). Calci-
fication of the pulmonary arteries or ductus arteriosus may 
be visible.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3).  Chest-x-ray in ES with prominent, dilated main and 
branch pulmonary arteries and diminished size and number of pe-
ripheral vessels (pruning).  
  Patients with the ES due to VSD or PDA have usually a 
cardiothoracic ratio, which is normal or mildly increased. 
The left atrium and the left ventricle are not enlarged in pa-
tients with ES due to a previous left-to-right shunt at ven-
tricular level or at the level of the great arteries. In contrast, 
patients with ASD have cardiomegaly due to a volume-
overloaded right atrium and ventricle. Biventricular en-
largement can be seen in TGA, truncus arteriosus, or univen-
tricular hearts. 
5. MODERN IMAGING (ECHO, MRI, CT) 
5.1. Echo 
  Transthoracic echocardiography (TTE) is the first-line 
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sessment can be performed using spectral and color flow 
Doppler. Pulmonary artery pressures are estimated by the 
following equations: 
  systolic PAP = 4 vTR
2 + RAP, where vTR equals the 
peak velocity of the jet of tricuspid regurgitation on 
continuous wave Doppler (in m/s), provided there is no 
pulmonary stenosis [25]; RAP is estimated by the size 
and the diameter change of the inferior vena cava dur-
ing a “sniff” test [26] 
  diastolic PAP = 4 vPR-dia
2 + RAP, where vPR-dia equals 
the end-diastolic velocity of the pulmonary regurgita-
tion jet [27] 
  mean PAP = 4 vPR-max
2, where vPR-max  equals the 
maximum velocity of the pulmonary regurgitation jet 
  Two-dimensional anatomy is characterized by signs of 
chronic right ventricular pressure overload. The right ven-
tricular wall thickness is increased and there is flattening of 
the interventricular septum in systole as right ventricular 
pressure equals left ventricular systolic pressure. Initially 
right ventricular systolic function is preserved, but with more 
advanced disease the right ventricle will dilate, hypokinesis 
will occur, and eventually the right ventricle will fail.  
  There are several limitations in the evaluation of size, 
systolic function and mass of the right ventricle by transtho-
racic echocardiography. The American Society of Echocar-
diography has published recommendations for the evaluation 
of the size of the right ventricle, which rely on linear dimen-
sions and surface measurements in the apical four-chamber 
view [28]; volumetric measurements cannot be performed 
accurately because of the complex geometry of the right ven-
tricle. Hence, surrogate markers of right systolic ventricular 
function, such as fractional area shortening, tricuspid annular 
motion and systolic tissue Doppler velocities, are used in 
daily routine practice to describe right ventricular systolic 
function. 
 Three-dimensional  TTE  may circumvent some of the 
limitations in the volumetric assessment of the right ventricle 
in the future, but preliminary experience indicates that this 
technique is not applicable yet to all adult patients [29].  
 Two-dimensional  TTE  may also demonstrate the under-
lying cardiac defect, such as an ASD, large nonrestrictive 
VSD, AV-septal defect, PDA, AP-window or even more 
complex anomalies.  
  Color flow Doppler will document the flow-velocity, 
bidirectional or right-to-left shunt across the defect. How-
ever, the diagnosis of the defect may be difficult in adults 
due to poor acoustic windows and the equalization of pres-
sures in the systemic and pulmonary circulations. 
 Transesophageal  echocardiography  may be useful in 
patients with ES to rule out thrombi in the presence of atrial 
fibrillation prior to cardioversion [30] or in search of vegeta-
tions when endocarditis is suspected [31]; however, low 
oxygen saturation levels in these patients, and the potential 
need for sedation makes this examination uncomfortable and 
alternative imaging modalities should be considered if TTE 
is inconclusive. Meticulous monitoring and surveillance by 
an experienced team (incuding a cardiac anesthetist) is criti-
cal. 
5.2. Cardiac Magnetic Resonance (CMR) 
  Cardiac Magnetic Resonance (CMR) provides unre-
stricted access to the chest without exposure to ionizing ra-
diation. Thus it is ideally suited for longitudinal follow-up of 
adult CHD patients. CMR provides information on ventricu-
lar size and function regardless of chamber geometry, flow 
volumes, tissue characterization, viability and myocardial 
perfusion [32]. 
  In patients with ES, CMR has incremental value over 
TTE with regard to the evaluation of size, systolic function 
and muscle mass of the right ventricle, the assessment of the 
main and branch pulmonary arteries, and to exclude congeni-
tal cardiac defects that were not recognized during the echo-
cardiographic examination (e.g. PDA, aorto-pulmonary col-
lateral vessels). 
  In order to evaluate the right ventricle a stack of multiple 
transaxial cines is acquired, and analyzed using contempo-
rary CMR software. Although time consuming, right ven-
tricular volume measurements can be performed with good 
accuracy and reasonable reproducibility, particularly if con-
tour data have been stored in a database and are available for 
comparison at the time of follow-up studies. Reference re-
sults for right ventricular volumes and systolic function, ac-
cording to age and gender have been published [33]. Fur-
thermore, CMR is also capable to evaluate right ventricular 
mass; these measurements are still labor intensive and used 
at present mainly for research purposes at the present time 
[34].  
  However, CMR does have limitations when it comes to 
measure velocities of narrow regurgitant tricuspid or pulmo-
nary jets, and is thus unlikely to estimate pulmonary pres-
sures accurately. 
5.3. Computed Tomography (CT) 
 Computed  Tomography  (CT) provides excellent spatial 
resolution and it has been shown that CT angiography of 
the pulmonary arteries (CTPA) has good sensitivity in the 
diagnosis of pulmonary embolism [35]. Furthermore, it is 
known since Wood’s necropsy series that Eisenmenger pa-
tients may develop thrombi in the pulmonary arteries. Thus, 
several recent studies have used this imaging modality to 
examine the prevalence and risk factors for pulmonary arte-
rial thrombosis in patients with ES [36, 37]. 
  In these studies CT and CTPA showed enlargement, 
thrombosis, and mural calcification of the pulmonary artery 
and its proximal branches. Within the lung parenchyma, em-
bolic infarction, hemorrhage, neovascularity, lobular ground 
glass opacification, and hilar and intercostal collaterals were 
recognized. In Eisenmenger patients, neovascularity, lobular 
ground glass opacification, and hilar and intercostal collater-
als were more prevalent than in acyanotic pulmonary hyper-
tension (see also Part III “1.2.2 Bleeding and thrombotic 
diathesis”). 
  Although CT and CTPA help us to diagnose in situ 
thrombosis in patients with ES, the lack of prospective data 
to establish the usefulness of anticoagulation in this patient 
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tion, precludes a recommendation to implement this imaging 
modality in this group of patients on a regular basis.  
6. EXERCISING/CARDIOPULMONARY EXERCISE 
TEST (CPET) 
Exercise Physiology of the Pulmonary Circulation 
  Pulmonary blood flow has different characteristics from 
the systemic circulation: 
  Pulmonary vessels have a low basal tone; 
  Numerous extraordinary, short and thin-walled arterioles 
with a low resistance; 
  Sympathetic vasomotor nerves have no clear physiologi-
cal role; 
  Ventilation has an important impact on pulmonary vascu-
lar resistance; 
  Metabolic factors have no physiological role, except for 
oxygen, carbon dioxide and hydrogen that cause an op-
posite effect on the lung vessels than in the systemic vas-
culature; 
  Metabolic demands of the bronchi are met by a separate 
bronchial arterial supply. That supply is part of the sys-
temic circulation, causing a minor shunt by drainage into 
the pulmonary veins. 
  At rest, mainly the basal lung areas are perfused due to 
orthostasis. To prevent shunting in the most basal areas the 
Euler-Liljestrand [38] reflex causes a regional vasoconstric-
tion in hypoxic alveolar areas and redirects pulmonary blood 
flow to the better ventilated areas. In healthy people there is 
a large pulmonary blood flow reserve. This can be promoted 
by stimulating endothelial factors like nitric oxide and pros-
taglandins, or by relaxing the vascular smooth muscle cell 
directly. 
  During exercise endothelial nitric oxide production, 
measured by exhaled nitric oxide, rises in proportion to ven-
tilation [39] Pulmonary vascular resistance declines to limit 
elevation of the mean pulmonary pressure. While Oelberg 
[40] found no increase of the systolic tricuspid regurgitation 
velocity (TRV) as a non-invasive substitute for the systolic 
right ventricular pressure, other studies reported on a moder-
ate increase of the TRV [41, 42]. Especially in athletes the 
previous definition of pulmonary hypertension in the ESC-
Guidelines of 2004 [43] with a mean PAP of more than 30 
mmHg at exercise is often met [41]. Some of these subjects 
are merely pre-symptomatic and at high risk to develop PAH 
later. Others, maybe, are not. Therefore, PAP at exercise was 
deleted from the diagnostic criteria in the current guidelines 
[2]. 
Exercise Physiology in Pulmonary Arterial Hypertension 
  In patients with pulmonary vascular disease, pulmonary 
vascular resistance does not display the physiologic decline 
during exercise. Even in asymptomatic genetic carriers of a 
familial form of primary pulmonary hypertension, a patho-
logical rise of pulmonary artery systolic pressure could be 
found [44]. Also patients with atrial septal defect show a 
decrease in exercise capacity correlating with the extensive 
increase of systolic pulmonary pressure during exercise [40]. 
Patients after repair of a ventricular septal defect showed an 
increase in mean arterial pulmonary pressure and a failure to 
decrease pulmonary vascular resistance if there was an ele-
vated pulmonary vascular resistance prior to surgery, or if 
surgery was performed too late [45].  
  In patients with ES the unrestrictive bidirectional shunt 
prevents suprasystemic right ventricular pressure and enables 
left ventricular filling. A right-to-left shunt at atrial level 
even augments left ventricular filling and may prevent heart 
failure during exercise, however, at the expense of cyanosis 
during exercise [46].  
  The amount of right to left shunting through a large, un-
restrictive ventricular septal defect depends on the ratio of 
pulmonary to systemic vascular resistance (Rp/Rs). In Eisen-
menger patients systemic vascular resistance decreases sub-
stantially during exercise, whereas pulmonary vascular resis-
tance decreases inadequately. The ratio of pulmonary to sys-
temic vascular resistance, which might be less than 1 at rest, 
increases to more than 1 during exercise. Severe cyanosis 
reaching saturations of less than 50% causes dyspnea and 
makes patients stop exercise [46].  
  In addition to the findings in patients with pulmonary 
hypertension without shunt (reduced peak work load, oxygen 
uptake (V’O2), oxygen pulse, heart rate, ventilation, systolic 
blood pressure, ventilatory threshold, V’O2 to work load 
slope, and V’O2 to heart rate slope; increased ratio of ventila-
tory threshold to peak V’O2 and especially the V’E/V’CO2 
slope [47-49]), the right-to-left shunting in Eisenmenger pa-
tients provokes a further increase in the V’E/V’CO2 slope 
[50], a further increase in end-tidal partial pressure of O2, a 
further decrease in end-tidal CO2, an increase in the respira-
tory exchange ratio (V’CO2/V’O2) [51], and a decline of the 
oxygen pulse. Despite low arterial oxygen saturation, only 
few patients report on central nervous symptoms like dizzi-
ness. However, ECG repolarization abnormalities, including 
T-wave inversion or ST-segment depression, similar to those 
seen in ischemic heart disease, are common. 
PAH and Sports 
  As many congenital cardiologists have seen pulmonary 
hypertensive crises in the postoperative management of pa-
tients with pulmonary hypertension [52], they fear to pro-
voke a pulmonary hypertensive crisis by exercise. However, 
during laboratory exercise tests these events are hardly re-
ported [47]. Moreover, none of the 61 deaths Daliento et al 
[53] reported on were related to sporting activities. 
  Nevertheless, for Eisenmenger patients a recent recom-
mendation for participation in competitive and leisure sport 
[54] allows only low dynamic sport leisure activities and 
forbids competitive sports. Patients with ES may not perform 
scuba diving. Decompression in commercial airlines causes 
less desaturations than sports [55]. Patients report on travel-
ling frequently and safely [56] (see also Part III “1.9 Travel 
to high altitude / Air flight”). 
Exercise Training as a Therapeutic Concept in PAH 
  Regular exercise training improves endothelial function 
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and improves survival [58]. An animal model [59], trying to 
translate these improvements to the pulmonary vessels, 
failed to show positive effects of exercise training to pulmo-
nary hypertensive rats.  
  However, patients with idiopathic or chronic throm-
boembolic pulmonary hypertension [60] had a benefit from 
exercise training in respect to an increased six minute walk-
ing distance, peak V’O2, ventilatory threshold, and peak 
achieved work load. Additionally, quality of life improved. 
No adverse events were reported. Nevertheless, changes in 
the hemodynamics could not be found. Perhaps, exercise 
training may mainly result in an improvement of the periph-
eral exercising muscles, and not of the pulmonary vascular 
bed [61]. Evidence of improved survival is lacking. 
7. HAEMODYNAMICS/CARDIAC CATHETERIZA-
TION 
  The main purpose in cardiac catheterization of a patient 
with ES is to determine vascular physiology and to assess 
pulmonary vascular reactivity to vasoactive substances such 
as oxygen, nitric oxide and prostacyclin. Based on these 
measurements therapeutic decisions on treatment with vaso-
active substances, catheter interventions, or surgery can be 
made. 
  In the following, a practical guideline is given how to 
acquire relevant hemodynamic data for decision making in 
PAH due to congenital cardiac lesions and to discuss poten-
tial pitfalls in the interpretation of the measured data [62, 
63]. 
Cardiac Catheterization 
  Patients are often examined with mild conscious seda-
tion, breathing spontaneously, to avoid hemodynamic side 
effects of general anesthesia. A CO2 value < 45 mmHg is 
acceptable during the examination. Higher CO2 values may 
significantly alter vascular resistance. To obtain exact data, 
oxygen consumption (VO2) is measured by the polarographic 
method. The tables of LaFarge and Mietinnen [64] were re-
lying on healthy young individuals and hence tend to overes-
timate oxygen consumption. For this reason these table val-
ues are not acceptable to determine accurate data in adults 
with ES.  
  Usually, a femoral vein and artery are used for vascular 
access. An end open balloon catheter (pulmonary venous 
wedge catheter) is placed distally into a pulmonary artery. 
Systemic arterial pressures and oxygen saturations are as-
sessed via the femoral artery or the aorta.  
  Blood samples are collected in the superior and inferior 
vena cava, the pulmonary artery, the left atrium (pulmonary 
venous wedge position) and in the systemic artery.  
  Measurement is carried out in several conditions: room 
air, 20-40 ppm nitric oxide, 100% oxygen and nitric oxide 
20-40 ppm, inhaled prostacyclin. Every substance needs to 
be applied for at least ten minutes in a steady state. In each 
condition pressures are recorded in the right atrium, left 
atrium (pulmonary venous wedge position), pulmonary ar-
tery, and the aorta. Blood samples are collected in the supe-
rior and inferior vena cava, the pulmonary artery, the left 
atrium (pulmonary venous wedge position) and the aorta. 
The oxygen saturation of the blood probes is measured using 
a spectrophotometric method.  
Oximetry 
 Oxygen  saturation is the proportion of oxygen bound to 
hemoglobin divided by the oxygen capacity: 
O2 saturation = (O2 content - dissolved O2) x 100 / O2 capa-
city. 
 The  oxygen content is the total amount of oxygen pre-
sent in a blood sample. It is a combination of the oxygen 
bound to hemoglobin plus the dissolved oxygen.  
 The  oxygen capacity (in mL O2/L) can also be calculated 
by multiplying the hemoglobin (in g/dL) by 13.6. This is 
because each gram of hemoglobin in a liter of blood will 
combine with 13.6 mL of oxygen when the hemoglobin is 
fully (100%) saturated [65].  
  In contrast to the measurement of oxygen content by the 
original method of Van Slyke [66] the contemporarily used 
spectrophotometric method for oxygen saturation assessment 
does not measure the dissolved oxygen present in the probe. 
Under room air condition this is negligible, since the amount 
of dissolved oxygen is only about 1% of the amount of oxy-
gen combined with the hemoglobin (0.03 mL/O2/mmHg in 
1.0 L of blood). However, if the patient breathes 100% oxy-
gen the amount of dissolved oxygen rises significantly. Ad-
ditional assessment of the pO2 by blood gas analysis enables 
to take the dissolved oxygen into consideration. Blood flow 
can then be calculated using the formulas in Table 5. 
Table 5.  Calculations for Hemodynamic Assessments 
Qp   =   VO2 / PVO2 - PaO2 =    VO2 / [(PVsat - PAsat) (O2 capacity)] 
Qs  =    VO2 / SAO2 - MVO2   =   VO2 / [(SAsat - MVsat) (O2 capacity)] 
Qep   =  VO2 / PVO2 - MVO2 =  VO2 / [(PVsat - MVsat) (O2 capacity)] 
Qp/Qs =  (SAsat - MVsat) / (PVsat - PAsat) 
Left-to-right shunt   =  Qp - Qep 
Right-to-left shunt  =  Qs - Qep 
O2 capacity = 13.6 x gm Hb/dL 
Legend: Qp = pulmonary blood flow, Qs = systemic blood flow, Qep = effective pulmonary blood flow, VO2 = oxygen consumption, PVsat = pulmonary venous O2 saturation, PAsat = 
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Resistance 
 To  calculate  vascular  resistances Ohm’s and Hagen 
Poiseuille’s laws are applied. It is of note that vessel radius 
enters the denominator of the formula in the forth power. 
Hence, a smaller vessel diameter, as seen in pulmonary vas-
cular disease, has significant impact on pulmonary vascular 
resistance (Table 6). 
Table 6.  Calculations for Assessment of Vascular Resistances 
Rp  =  mPAP - mPVP / Qp 
Rs  =  mAOP - mRAP / Qs  
Legend: Rp and Rs = pulmonary and systemic vascular resistance. mPAP = mean 
pulmonary arterial pressure, mPVP = mean pulmonary venous (left atrial, pulmonary 
venous wedge) pressure, mAOP = mean systemic arterial pressure, mRAP = mean 
right atrial pressure 
 
  The resistance is expressed in mm Hg x minute x 1-1 
(hybrid resistance units or Wood units) [67]. Multiplying by 
80 converts Wood units to the centimeter-gram-seconds sys-
tem, where units are dynes x seconds x cm
-5.  
 Normal  systemic resistance (Rs) is 13 to 18 units x m
2. 
Normal pulmonary arteriolar resistance (Rp) is less than 2 
units x m
2.  
  It is important to note that for indexing Wood units to 
body surface area, they need to be multiplied (!) by BSA 
[68]. 
Interpretation of the Hemodynamic Results 
 Q p, Qs, Rp and Rs are calculated in all conditions. In gen-
eral, patients with Eisenmenger reaction pulmonary arterial 
pressures equal systemic arterial pressures due to the large 
communication between the systemic and pulmonary circu-
lation. The severity of pulmonary arteriopathy is expressed 
by the pulmonary vascular resistance and the reactivity to 
vasoactive substances.  
  In adults with this disease under room air Rp is equal to 
or greater than Rs. This results in moderate to severe right-to-
left shunt with subsequent cyanosis. If however, after expo-
sure to oxygen and nitric oxide, Rp falls to below 5 units x 
m
2 and a resistance ratio of less than 0.4/1, this would result 
in significant left-to-right shunt. It is possible that in this 
case pulmonary pressure and eventually pulmonary vascular 
resistance will diminish with repair of this lesion [69].  
  Most patients with Eisenmenger reaction, however, are 
beyond the point to consider corrective therapy. An Rp of > 
10 units x m
2 and Rp/Rs of greater than 0.7/1 usually indi-
cates that corrective treatment (surgery/ catheter interven-
tion) is associated with an increased risk for morbidity and 
mortality. These patients will not benefit from this approach. 
If however, Rp or Rp/Rs drops by more than 20% during ex-
posure to oxygen and nitric oxide, medical treatment with 
vasoactive agents is indicated and may result in significant 
improvement of quality of life. 
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